NOVO HOLDINGS A/S
An institutional investment manager in HELLERUP. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1388325.
- Reported value$1.72bn
- Positions25
Holdings: 25 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 217 | 12.6% | 5,350,000 | Unchanged | |
| Asml Holding N V | N Y REGISTRY SHS | N07059210 | 189 | 11.0% | 94,946 | Unchanged | |
| Hemab Therapeutics Holdings IncCOAG | COM SHS | 423494103 | 154 | 8.9% | 4,180,550 | New+4,180,550 | |
| Brookfield CorpBN | CL A LTD VT SH | 11271J107 | 150 | 8.7% | 3,496,245 | Unchanged | |
| Maplight Therapeutics IncMPLT | COM | 56565P103 | 132 | 7.7% | 3,686,622 | Unchanged | |
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 132 | 7.6% | 1,125,000 | Reduced−200,000 | |
| Avalyn Pharmaceuticals IncAVLN | COM SHS | 05348Y105 | 128 | 7.4% | 3,883,289 | New+3,883,289 | |
| Salesforce IncCRM | COM | 79466L302 | 61.6 | 3.6% | 393,187 | Unchanged | |
| Arrivent Biopharma IncAVBP | COM | 04272N102 | 52.1 | 3.0% | 1,500,000 | Reduced−442,142 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 50.8 | 2.9% | 1,000,000 | Reduced−280,000 | |
| Crinetics Pharmaceuticals in | COM | 22663K107 | 49.4 | 2.9% | 1,320,000 | Reduced−230,000 | |
| Pharvaris N V | COM | N69605108 | 48.4 | 2.8% | 1,400,000 | Reduced−350,000 | |
| Floor & Decor Holdings IncFND | CL A | 339750101 | 47.3 | 2.7% | 797,000 | New+797,000 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 46.5 | 2.7% | 800,000 | Reduced−60,000 | |
| 4D Molecular Therapeutics inFDMT | COM | 35104E100 | 43.2 | 2.5% | 3,249,178 | Reduced−401,559 | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 39.2 | 2.3% | 2,135,000 | Added+135,000 | |
| Celldex Therapeutics Inc NewCLDX | COM NEW | 15117B202 | 38.1 | 2.2% | 1,025,000 | Reduced−175,000 | |
| Alumis IncALMS | COM | 022307102 | 31.0 | 1.8% | 1,100,000 | New+1,100,000 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 29.3 | 1.7% | 485,438 | Unchanged | |
| Alibaba Group HLDG LtdBABA | SPONSORED ADS | 01609W102 | 24.7 | 1.4% | 257,327 | Unchanged | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 21.3 | 1.2% | 960,394 | New+960,394 | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 17.1 | 1.0% | 2,250,000 | Added+64,077 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 12.9 | 0.7% | 120,723 | New+120,723 | |
| Marqeta Inc | CLASS A COM | 57142B104 | 7.2 | 0.4% | 441,558 | Unchanged | |
| Lanzatech Global IncLNZA | COM NEW | 51655R200 | 1.1 | <0.1% | 158,148 | Unchanged |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−450,000 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 0.0 | 0.0% | 0 | Sold out−660,000 | |
| Valneva SEVALN | SPONSORED ADS | 92025Y103 | 0.0 | 0.0% | 0 | Sold out−1,057,421 |
Source: SEC EDGAR, Form 13F-HR, accession 0001388325-26-000042 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.